Brought to you by 
Synthetic Genomics, United Therapeutics, Lung Biotech ally in organ transplants
02 Feb 2023
Executive Summary
In a multi-year agreement, Synthetic Genomics Inc. (SGI; DNA-based products) is partnering with United Therapeutics Corp. and its Lung Biotechnology Inc. subsidiary to use synthetic genomics in the development of humanized pig organs for patients who will receive lung transplants.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Transgenics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synthetic Genomics, United Therapeutics, Lung Biotech ally in organ transplants
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice